GlassScriptPhysician profile
Sabrina Torres
NPI 1487344677
$4,575.89
in general payments reported to CMS, 2019-2025
29 companies · $3,448 in 2025
The $3,448 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $30.34 · 2024: $1,098 · 2025: $3,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,476 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,475.90 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $1,154.34 | 2025 | Zoryve |
| Janssen Biotech, INC. | $584.86 | 2023-2025 | Tremfya, Darzalex, Erleada |
| Incyte Corporation | $361.69 | 2024-2025 | Opzelura, Jakafi |
| Abbvie INC. | $319.79 | 2024-2025 | |
| Ucb, INC. | $260.96 | 2025 | Bimzelx |
| Astrazeneca Pharmaceuticals LP | $233.18 | 2024 | Imfinzi, Enhertu, Tagrisso |
| Merck Sharp & Dohme LLC | $222.05 | 2024 | Keytruda, Lynparza, Welireg |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $171.70 | 2025 | Jublia, Cabtreo, Siliq |
| Regeneron Healthcare Solutions, INC. | $159.70 | 2025 | Dupixent |
| Lilly USA, LLC | $132.87 | 2024-2025 | Taltz, Ebglyss, Verzenio |
| E.R. Squibb & Sons, L.L.C. | $122.82 | 2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $115.58 | 2025 | |
| Almirall LLC | $110.67 | 2025 | Klisyri |
| Galderma Laboratories, L.P. | $75.09 | 2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $69.78 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $63.82 | 2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $50.48 | 2024 | |
| Leo Pharma INC. | $50.10 | 2025 | Anzupgo, Adbry |
| Teva Pharmaceuticals USA, INC. | $43.26 | 2025 | Uzedy |
| Recordati_rare_diseases_inc. | $42.39 | 2024 | Sylvant |
| Stemline Therapeutics INC. | $36.60 | 2024 | Orserdu |
| Genzyme Corporation | $34.47 | 2025 | |
| Biocon Biologics INC | $32.22 | 2024 | Fulphila |
| Takeda Pharmaceuticals U.S.A., INC. | $26.73 | 2024 | Ninlaro |
| Amgen INC. | $23.43 | 2025 | Evenity |
| Myriad Genetic Laboratories, INC. | $21.52 | 2024 | Precisetumor |
| Eisai INC. | $19.62 | 2024 | |
| Sumitomo Pharma America, INC. | $19.51 | 2024 | Orgovyx |
| Genentech USA, INC. | $16.66 | 2024 | Ocrevus, Xolair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabrina Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.